Figures & data
Figure 2. Particle characterization of DOX-loaded MS. (A) Size distribution profiles of DOX MS and DOX/HACE MS. (B) CLSM images of DOX MS and DOX/HACE MS. Depth-dependent cross-sectional images were observed by CLSM. Red fluorescence signal in MS indicates the intraparticle distribution of DOX. The length of the scale bar is 5 μm. (C) Particle characteristics of released DOX/HACE nanoassembly from DOX/HACE MS after incubating for 7 days. Size distribution profile (left) and TEM image (right) are presented. The length of the scale bar in the TEM image is 500 nm.
![Figure 2. Particle characterization of DOX-loaded MS. (A) Size distribution profiles of DOX MS and DOX/HACE MS. (B) CLSM images of DOX MS and DOX/HACE MS. Depth-dependent cross-sectional images were observed by CLSM. Red fluorescence signal in MS indicates the intraparticle distribution of DOX. The length of the scale bar is 5 μm. (C) Particle characteristics of released DOX/HACE nanoassembly from DOX/HACE MS after incubating for 7 days. Size distribution profile (left) and TEM image (right) are presented. The length of the scale bar in the TEM image is 500 nm.](/cms/asset/f9504793-44d2-4f08-b337-77d3bf115dc4/idrd_a_1480673_f0002_c.jpg)
Figure 3. In vitro degradation test of fabricated MS. DOX MS (A) and DOX/HACE MS (B) were incubated in PBS (pH 7.4) and FBS for 14 days. The morphology of MS was observed by SEM (scale bar = 20 μm). Inset with the yellow boundary indicates the magnified image (scale bar = 2 μm).
![Figure 3. In vitro degradation test of fabricated MS. DOX MS (A) and DOX/HACE MS (B) were incubated in PBS (pH 7.4) and FBS for 14 days. The morphology of MS was observed by SEM (scale bar = 20 μm). Inset with the yellow boundary indicates the magnified image (scale bar = 2 μm).](/cms/asset/80268073-1ab6-4e52-a41a-4d7f1055ebcd/idrd_a_1480673_f0003_c.jpg)
Figure 4. Drug release profiles from DOX MS (pH: 7.4) and DOX/HACE MS (pH: 7.4, 6.8, and 5.5). Each point indicates the mean ± SD (n = 3).
![Figure 4. Drug release profiles from DOX MS (pH: 7.4) and DOX/HACE MS (pH: 7.4, 6.8, and 5.5). Each point indicates the mean ± SD (n = 3).](/cms/asset/559b1a6d-6a27-43d7-98d9-19717e679b6a/idrd_a_1480673_f0004_b.jpg)
Figure 5. Cellular accumulation efficiency and in vitro anticancer activities in HepG2 and McA-RH7777 cells. (A) The mean fluorescence intensity values of DOX, measured by flow cytometry, in HepG2 cells and McA-RH7777 cells. Each point indicates the mean ± SD (n = 3). *p < .05, compared with DOX group. #p < .05, compared with DOX MS group. (B) Antiproliferation efficacy, evaluated by MTS-based assay, of DOX-loaded MSs in HepG2 cells and McA-RH7777 cells. Cell viability (%) is presented as the relative percentage based on the control (no treatment) group. Each point indicates the mean ± SD (n = 3). #p < .05, compared with DOX MS group. (C) Apoptotic efficacy of developed MS, measured by Annexin V and PI-based assays, in HepG2 cells and McA-RH7777 cells. UL, LL, LR, and UR indicate upper left, lower left, lower right, and upper right, respectively. Each point indicates the mean ± SD (n = 3). *p < .05, compared with DOX group. #p < .05, compared with DOX MS group.
![Figure 5. Cellular accumulation efficiency and in vitro anticancer activities in HepG2 and McA-RH7777 cells. (A) The mean fluorescence intensity values of DOX, measured by flow cytometry, in HepG2 cells and McA-RH7777 cells. Each point indicates the mean ± SD (n = 3). *p < .05, compared with DOX group. #p < .05, compared with DOX MS group. (B) Antiproliferation efficacy, evaluated by MTS-based assay, of DOX-loaded MSs in HepG2 cells and McA-RH7777 cells. Cell viability (%) is presented as the relative percentage based on the control (no treatment) group. Each point indicates the mean ± SD (n = 3). #p < .05, compared with DOX MS group. (C) Apoptotic efficacy of developed MS, measured by Annexin V and PI-based assays, in HepG2 cells and McA-RH7777 cells. UL, LL, LR, and UR indicate upper left, lower left, lower right, and upper right, respectively. Each point indicates the mean ± SD (n = 3). *p < .05, compared with DOX group. #p < .05, compared with DOX MS group.](/cms/asset/5ccdf21b-ced2-40ca-a8bc-0d91acbd8e59/idrd_a_1480673_f0005_c.jpg)
Figure 6. In vivo anticancer activities in the McA-RH7777 tumor-implanted rat model. (A) Serial MR images of liver tumors in control (sham operation), DOX MS, and DOX/HACE MS groups on day 0 (pre-treatment status), 3, and 7 after IA administration. White arrowheads in MR images indicate liver tumor. The length of scale bar in the left side is 1 cm. (B) H&E staining images of dissected liver and tumor, lung, spleen, kidney, and heart in control, DOX MS, and DOX/HACE MS groups. The length of scale bar (shown in the lower right side) in the images of lung, spleen, kidney, and heart is 100 μm.
![Figure 6. In vivo anticancer activities in the McA-RH7777 tumor-implanted rat model. (A) Serial MR images of liver tumors in control (sham operation), DOX MS, and DOX/HACE MS groups on day 0 (pre-treatment status), 3, and 7 after IA administration. White arrowheads in MR images indicate liver tumor. The length of scale bar in the left side is 1 cm. (B) H&E staining images of dissected liver and tumor, lung, spleen, kidney, and heart in control, DOX MS, and DOX/HACE MS groups. The length of scale bar (shown in the lower right side) in the images of lung, spleen, kidney, and heart is 100 μm.](/cms/asset/2c1d714c-eb28-45a9-ac61-ebb0a720d1a1/idrd_a_1480673_f0006_c.jpg)